Skip to content

GRAIL, Inc. GRAL Return on equity

Return on equity at other companies

Abbott logo
AbbottABT
12.4%-18.4pp
Guardant Health logo
Guardant HealthGH
-438.1%-1,655pp
Natera, Inc. logo
Natera, Inc.NTRA
-29%+4.1pp
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
-81.6%
Immunome logo
ImmunomeIMNM
-50.1%-10.8pp
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
-24.4%-9.2pp

Other financials

Income statement

See full
Revenue$40.8M+28.1%
Operating income-$135.8M+11.6%
Net income-$93.2M+12.3%
EPS (diluted)-$2.29+26.1%

Balance sheet

See full
Cash & equivalents$76.3M-44.4%
Total debt$51.0M-20.7%
Total equity$2.5B+3.6%
Total assets$2.8B-1.5%

Cash flow

See full
Operating cash flow-$87.0M+8.4%
CapEx$503.0K+711%
Free cash flow-$87.5M+8.0%

Valuation

See full
Market cap$2.62B+145%
Enterprise value$2.6B+164%
P/S16.8×+8.6×

Profitability

See full
Operating margin-348.7%-153pp
Net margin-253.2%-115pp
FCF margin-187.2%-60.4pp

Returns & leverage

See full
Debt / equity0.0×
Current ratio11.7×+2.0×

Where this comes from

Calculated from GRAIL, Inc.’s reported figures.

Based on trailing twelve months.

The official record: GRAIL, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about GRAIL, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GRAIL, Inc.'s return on equity?
GRAIL, Inc. (GRAL) reported return on equity of -16.1% in Q1 2026.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.